Overview
Switzerland industrial group's 2025 revenue fell sharply, mainly due to Belimed divestment
EBIT and net income turned negative, weighed by one-off costs and weak market demand
Company will not pay a dividend for 2025 to maintain financial flexibility
Outlook
Company expects business to stabilize as investments and cost reductions take effect
Metall Zug believes 2025 results mark the bottom of the cycle, sees growth potential
Company says uncertainties around geopolitics, tariffs and US dollar developments persist
Result Drivers
WEAK US DEMAND & TARIFFS - Co said weaker US dollar, new US tariffs, and cautious investment environment led to lower sales and modest order intake, especially in Medical Devices
ONE-OFF COSTS - EBIT was weighed by CHF 5.1 mln in product phase-out costs and CHF 0.6 mln in restructuring charges in Medical Devices
COMPETITION & PRICE PRESSURE - Increased competition and price pressure, especially in Simulation and General Diagnostics, contributed to sales decline in Medical Devices
Company press release: ID:nEQgJkpha
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
CHF 194.6 mln
FY EBIT
-CHF 17.5 mln
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the appliances, tools & housewares peer group is "buy."
The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 33 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)